PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
Daniele SantiniTea ZeppolaMarco RussanoFabrizio CitarellaCecilia AnesiSebastiano ButiMarco TucciAlessandro RussoMaria Chiara SergiVincenzo AdamoLuigia S StucciMelissa BersanelliGiulia MazzaschiFrancesco SpagnoloFrancesca RastelliFrancesca Chiara GiorgiRaffaele GiustiMarco FilettiPaolo MarchettiAndrea BotticelliAlain GelibterMarco SiringoMarco FerrariRiccardo MarconciniMaria Giuseppa VitaleLinda NicolardiRita ChiariMichele GhidiniOlga NigroFrancesco GrossiMichele De TursiPietro Di MarinoLaura PalaPaola QueiroloSergio BracardaSerena MacriniStefania GoriAlessandro InnoFederica ZorattoEnrica T TandaDomenico MallardoMaria Grazia VitaleThomas TalbotPaolo A AsciertoDavid J PinatoCorrado FicorellaGiampiero PorzioAlessio CortelliniPublished in: Journal of translational medicine (2021)
Our results confirmed a trend toward an increasing ICIs prescription in frail patients, during the late stages of life. Caution should be exercised when evaluating an ICI treatment for patients with a poor PS and a high burden of disease.